Drug Trial Radar · NCT06095128
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Jul 9, 2027
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Conditions
- Ulcerative Colitis
Interventions
VedolizumabDrug
Vedolizumab IV infusions
TofacitinibDrug
Tofacitinib Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo ScoreTime frame: At Week 8
Locations
45 sites in 2 countries. Site status is shown where the registry gives one.
Digestive Health Specialsits
Dothan, Alabama
GI Alliance Sun City
Sun City, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
Hoag Hospital Newport Beach
Newport Beach, California
Endoscopic Research Inc
Orlando, Florida
Alliance Clinical Research of Tampa, LLC
Tampa, Florida
Gastroenterology Consultants, P.C.
Roswell, Georgia
University of Chicago Medicine
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
University of Louisville
Louisville, Kentucky
GI Alliance
Metairie, Louisiana
Tulane University
New Orleans, Louisiana
Capital Digestive Care - MGG Group - Chevy Chase Clinical Research
Chevy Chase, Maryland
Huron Gastroenterology Associates, P.C.
Ypsilanti, Michigan
MNGI Digestive Health, PA
Plymouth, Minnesota
Mid-America Gastro-Intestinal Consultants
Kansas City, Missouri
BVL Clinical Research
Liberty, Missouri
Washington University School of Medicine
St Louis, Missouri
NYU Langone Health
New York, New York
Weill Cornell Medical College- New York Presbyterian Hospital
New York, New York
Digestive Health Partners
Asheville, North Carolina
University of North Carolina
Chapel Hill, North Carolina
University of Cincinnati
Cincinnati, Ohio
Ohio Gastroenterology group, Inc.
Columbus, Ohio
Gastro Intestinal Research Institute of Northern Ohio, LLC.
Westlake, Ohio
Allegheny Health Network
Wexford, Pennsylvania
University Gastroenterology
Providence, Rhode Island
Sanford Health Research
Rapid City, South Dakota
The University of Texas Health Science Center at Houston
Houston, Texas
GI Alliance - Mansfield
Mansfield, Texas
Gastroenterology Research of San Antonio, LLC
San Antonio, Texas
Texas Digestive Disease Consultants (TDDC), Southlake
Southlake, Texas
Tyler Research Institute, LLC
Tyler, Texas
GI Alliance - Webster
Webster, Texas
University of Utah Health
Salt Lake City, Utah
Washington Gastroenterology- GIA
Tacoma, Washington
Barrie GI Associates Inc.
Barrie, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
West GTA Endoscopy Inc.
Mississauga, Ontario, Canada
Viable Clinical Research - North Bay
North Bay, Ontario, Canada
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.